TY - JOUR
T1 - 18F-FNDP for PET Imaging of Soluble Epoxide Hydrolase
AU - Horti, Andrew G.
AU - Wang, Yuchuan
AU - Minn, Il
AU - Lan, Xi
AU - Wang, Jian
AU - Koehler, Raymond C.
AU - Alkayed, Nabil J.
AU - Dannals, Robert F.
AU - Pomper, Martin G.
N1 - Funding Information:
The costs of publication of this article were defrayed in part by the payment of page charges. Therefore, and solely to indicate this fact, this article is hereby marked advertisement in accordance with 18 USC section 1734. Financial support for this work was provided by NIH grants NS089437, NS078026, AT007317, NS038684, and NS060703; a DoD grant GW130098; an AHA Mid-Atlantic Affiliate grant-in-Aid 13GRNT15730001; a Postdoctoral Fellowship Award 15POST25090114 (XL); and, in part, by the Division of Nuclear Medicine and Molecular Imaging of Johns Hopkins University. No other potential conflict of interest relevant to this article was reported.
Publisher Copyright:
© 2016 by the Society of Nuclear Medicine and Molecular Imaging, Inc.
PY - 2016/11/1
Y1 - 2016/11/1
N2 - Soluble epoxide hydrolase (sEH) is a bifunctional enzyme located within cytosol and peroxisomes that converts epoxides to the corresponding diols and hydrolyzes phosphate monoesters. It serves to inactivate epoxyeicosatrienoic acids (EETs), which are generated in the brain to couple neuronal activity and cerebral blood flow in normal and pathologic states. Altered regulation of sEH was observed previously in various neuropathologic disorders including vascular dementia and stroke. Inhibitors of sEH are pursued as agents tomitigate neuronal damage after stroke. We developed N-(3,3-diphenylpropyl)- 6-18F-fluoronicotinamide (18F-FNDP), which proved highly specific for imaging of sEH in the mouse and nonhuman primate brain with PET. Methods: 18F-FNDP was synthesized from the corresponding bromo precursor. sEH inhibitory activity of 18F-FNDP was measured using an sEH inhibitor screening assay kit. Biodistribution was undertaken in CD-1 mice. Binding specificity was assayed in CD-1 and sEH knock-out mice and Papio anubis (baboon) through pretreatment with an sEH inhibitor to block sEH binding. Dynamic PET imaging with arterial blood sampling was performed in 3 baboons, with regional tracer binding quantified using distribution volume. The metabolism of 18F-FNDP in baboons was assessed using high-performance liquid chromatography. Results: 18F-FNDP (inhibition binding affinity constant, 1.73 nM) was prepared in 1 step in a radiochemical yield of 14% ± 7%, specific radioactivity in the range of 888-3,774 GBq/μmol, and a radiochemical purity greater than 99% using an automatic radiosynthesis module. The time of preparation was about 75 min. In CD-1 mice, regional uptake followed the pattern of striatum . cortex . hippocampus . cerebellum, consistent with the known brain distribution of sEH, with 5.2% injected dose per gram of tissue at peak uptake. Blockade of 80%-90% was demonstrated in all brain regions. Minimal radiotracer uptake was present in sEH knock-out mice. PET baboon brain distribution paralleled that seen in mouse, with a marked blockade (95%) noted in all regions indicating sEH-mediated uptake of 18F-FNDP. Two hydrophilic metabolites were identified, with 20% parent compound present at 90 min after injection in baboon plasma. Conclusion: 18F-FNDP can be synthesized in suitable radiochemical yield and high specific radioactivity and purity. In vivo imaging experiments demonstrated that 18F-FNDP targeted sEH in murine and nonhuman primate brain specifically. 18F-FNDP is a promising PET radiotracer likely to be useful for understanding the role of sEH in a variety of conditions affecting the central nervous system.
AB - Soluble epoxide hydrolase (sEH) is a bifunctional enzyme located within cytosol and peroxisomes that converts epoxides to the corresponding diols and hydrolyzes phosphate monoesters. It serves to inactivate epoxyeicosatrienoic acids (EETs), which are generated in the brain to couple neuronal activity and cerebral blood flow in normal and pathologic states. Altered regulation of sEH was observed previously in various neuropathologic disorders including vascular dementia and stroke. Inhibitors of sEH are pursued as agents tomitigate neuronal damage after stroke. We developed N-(3,3-diphenylpropyl)- 6-18F-fluoronicotinamide (18F-FNDP), which proved highly specific for imaging of sEH in the mouse and nonhuman primate brain with PET. Methods: 18F-FNDP was synthesized from the corresponding bromo precursor. sEH inhibitory activity of 18F-FNDP was measured using an sEH inhibitor screening assay kit. Biodistribution was undertaken in CD-1 mice. Binding specificity was assayed in CD-1 and sEH knock-out mice and Papio anubis (baboon) through pretreatment with an sEH inhibitor to block sEH binding. Dynamic PET imaging with arterial blood sampling was performed in 3 baboons, with regional tracer binding quantified using distribution volume. The metabolism of 18F-FNDP in baboons was assessed using high-performance liquid chromatography. Results: 18F-FNDP (inhibition binding affinity constant, 1.73 nM) was prepared in 1 step in a radiochemical yield of 14% ± 7%, specific radioactivity in the range of 888-3,774 GBq/μmol, and a radiochemical purity greater than 99% using an automatic radiosynthesis module. The time of preparation was about 75 min. In CD-1 mice, regional uptake followed the pattern of striatum . cortex . hippocampus . cerebellum, consistent with the known brain distribution of sEH, with 5.2% injected dose per gram of tissue at peak uptake. Blockade of 80%-90% was demonstrated in all brain regions. Minimal radiotracer uptake was present in sEH knock-out mice. PET baboon brain distribution paralleled that seen in mouse, with a marked blockade (95%) noted in all regions indicating sEH-mediated uptake of 18F-FNDP. Two hydrophilic metabolites were identified, with 20% parent compound present at 90 min after injection in baboon plasma. Conclusion: 18F-FNDP can be synthesized in suitable radiochemical yield and high specific radioactivity and purity. In vivo imaging experiments demonstrated that 18F-FNDP targeted sEH in murine and nonhuman primate brain specifically. 18F-FNDP is a promising PET radiotracer likely to be useful for understanding the role of sEH in a variety of conditions affecting the central nervous system.
KW - Baboon
KW - Epoxyeicosatrienoic acid
KW - Molecular neuroimaging
KW - Positron emission tomography
KW - Soluble epoxide hydrolase
KW - Stroke
KW - Vascular cognitive impairment
UR - http://www.scopus.com/inward/record.url?scp=84994860293&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84994860293&partnerID=8YFLogxK
U2 - 10.2967/jnumed.116.173245
DO - 10.2967/jnumed.116.173245
M3 - Article
C2 - 27417650
AN - SCOPUS:84994860293
SN - 0161-5505
VL - 57
SP - 1817
EP - 1822
JO - Journal of Nuclear Medicine
JF - Journal of Nuclear Medicine
IS - 11
ER -